+1 |BT| (S1 (S (NP (NP (NP (NP (JJ _PROT1_) (NN beta) (NN protein)) (PRN (-LRB- -LRB-) (NP (CD 25-35)) (-RRB- -RRB-))) (NN stimulation)) (PP (IN of) (NP (NP (NP (NP (NN _PROT2_) (NN A)) (, ,) (NP (NN C)) (CC and) (NP (NN D))) (NNS activities)) (PP (IN of) (NP (NN LA-N-2) (NNS cells)))))))) |ET|
-1 |BT| (S1 (S (LST (LS [3H) (-RRB- -RSB-)) (S (S (NP (NN Inositol) (JJ prelabeled) (NN LA-N-2) (NNS cells)) (VP (VBD were) (VP (VBN exposed) (PP (TO to) (NP (NP (JJ varying) (NNS concentrations)) (PP (IN of) (NP (DT _PROT1_) (NN _PROT1_) (NN _PROT1_))))) (, ,) (PP (IN from) (NP (QP (CD 20) (TO to) (CD 125)) (NNS micrograms/ml)))))) (, ,) (CC and) (S (NP (NP (NN _PROT2_) (NN _PROT2_)) (NN activation)) (VP (VBD was) (VP (VBN measured))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NNS effects)) (PP (IN of) (NP (JJ adrenergic) (, ,) (NP (NP (JJ metabotropic) (NN amino) (NN acid)) (CC and) (NP (NN bombesin))) (NNS antagonists))) (PP (IN on) (NP (NP (DT the) (ADJP (NN _PROT1_) (NN _PROT1_) (NN _PROT1_) (JJ mediated)) (NN stimulation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_) (NN activity)))))) (VP (VBD was) (VP (VBN investigated))))) |ET|
+1 |BT| (S1 (S (S (NP (NP (NN Propranolol)) (, ,) (NP (NP (DT a) (NN beta) (JJ adrenergic) (NN antagonist)) (, ,) (NP (JJ 7-chloro-kynurenic) (NN acid))) (, ,) (NP (DT a) (JJ metabotropic) (NN amino) (NN acid) (NN antagonist)) (, ,) (CC and) (NP (NN [Tyr4-D-Phe12)) (-RRB- -RSB-) (NP (NN bombesin)) (, ,) (NP (DT a) (NN bombesin) (NN antagonist)) (, ,)) (VP (VBD blunted) (NP (NP (DT the) (NN _PROT1_) (NN _PROT1_) (NN _PROT1_) (NN stimulation)) (PP (IN of) (NP (NP (NN _PROT2_) (NN _PROT2_)) (NN activity))) (PP (IN in) (NP (LST (LS [3H) (-RRB- -RSB-)) (NN inositol)))))) (NP (JJ prelabeled) (NN LA-N-2) (NNS cells)))) |ET|
+1 |BT| (S1 (S (NP (DT This)) (VP (VBZ suggests) (SBAR (IN that) (S (NP (NP (JJ _PROT1_) (NN beta) (NN protein) (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_)))) (VP (MD may) (VP (VB be) (NP (NP (NN receptor)) (VP (VBN mediated)))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (NN _PROT1_) (NN _PROT1_) (NN inhibitor)) (NP (NN U) (NN 71322))) (VP (VBD prevented) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_))) (PP (IN by) (NP (DT _PROT_) (NN _PROT_) (NN _PROT_))))))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (NN _PROT1_) (NN _PROT1_) (NN inhibitor)) (NP (NN U) (NN 71322))) (VP (VBD prevented) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT_) (NN _PROT_))) (PP (IN by) (NP (DT _PROT2_) (NN _PROT2_) (NN _PROT2_))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NN _PROT_) (NN _PROT_) (NN inhibitor)) (NP (NN U) (NN 71322))) (VP (VBD prevented) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_))) (PP (IN by) (NP (DT _PROT2_) (NN _PROT2_) (NN _PROT2_))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN _PROT1_) (NN secretion)) (CC and) (NP (NP (DT _PROT2_) (NN _PROT2_) (NN production)) (PP (IN in) (NP (NN NT2N) (NNS neurons))))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (DT the) (NN _PROT_) (NN _PROT_) (NN signal) (NN transduction) (NN pathway)))))))))) |ET|
+1 |BT| (S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN _PROT1_) (NN secretion)) (CC and) (NP (NP (DT _PROT_) (NN _PROT_) (NN production)) (PP (IN in) (NP (NN NT2N) (NNS neurons))))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN signal) (NN transduction) (NN pathway)))))))))) |ET|
+1 |BT| (S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (NN _PROT_) (NN secretion)) (CC and) (NP (NP (DT _PROT1_) (NN _PROT1_) (NN production)) (PP (IN in) (NP (NN NT2N) (NNS neurons))))) (VP (VBP are) (VP (VBN regulated) (PP (IN by) (NP (DT the) (NN _PROT2_) (NN _PROT2_) (NN signal) (NN transduction) (NN pathway)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (NP (JJ Current) (NN interest)) (PP (IN in) (NP (NN reducing) (NN heart) (NN disease) (NNS risks))) (PP (IN by) (NP (NN diet)))) (VP (VBZ involves) (NP (NP (NN attention)) (PP (TO to) (NP (JJ total) (NN fat)))))) (: ;) (S (NP (NP (ADJP (ADJP (JJ saturated)) (, ,) (ADJP (JJ monounsaturated)) (, ,) (ADJP (JJ polyunsaturated)) (CC and) (ADJP (JJ trans))) (JJ fatty) (NNS acids)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (NP (JJ dietary) (NN _PROT1_)) (, ,) (NP (JJ soluble) (NN fiber)) (, ,) (NP (NN salt)) (, ,) (NP (NN alcohol))) (, ,) (NP (NNS antioxidants)) (, ,) (NP (JJ dietary) (NNS alterations))) (VP (VBG causing) (NP (NP (NP (NN homocysteinemia)) (CC and) (NP (JJ other) (JJ dietary) (NNS constituents))) (, ,) (NP (ADJP (JJ such) (PP (IN as) (NP (NP (NN _PROT2_) (NNS compounds)) (PP (IN in) (NP (DT some) (NN soy)))))) (NNS products))))))) |ET|
+1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NP (JJ cAMP-dependent) (NN phosphorylation)) (PP (IN at) (NP (NP (DT a) (NN step)) (VP (VBG involving) (NP (JJ GTP-binding) (NN protein/PLC) (NN coupling)))))) (VP (MD can) (VP (VP (VB exert) (NP (DT a) (JJ negative) (NN effect)) (PP (IN on) (NP (NP (DT the) (NN stimulation)) (PP (IN of) (NP (NN _PROT1_) (NN formation))) (PP (IN by) (NP (NN _PROT2_)))))) (CC and) (RB thereby) (VP (VB affect) (NP (NP (NN contraction/relaxation)) (PP (IN in) (NP (DT the) (NN myometrium)))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NNS Roles)) (PP (IN of) (NP (NP (NN GTP)) (CC and) (NP (NN _PROT1_) (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion))) (PP (IN by) (NP (NN glucose))) (PP (IN in) (NP (NN rat) (JJ pancreatic) (NNS islets)))))))) |ET|
-1 |BT| (S1 (S (S (NP (EX There)) (VP (VBD was) (NP (NP (DT a) (ADJP (NP (CD 98) (NN %)) (JJR greater)) (NN augmentation)) (PP (IN of) (NP (NN _PROT1_) (NN secretion))) (PP (IN by) (NP (ADJP (CD 16.7) (NN mM)) (NN glucose)))) (-LRB- -LRB-) (PP (IN in) (NP (NP (DT the) (NN presence)) (PP (IN of) (NP (NP (NN diazoxide)) (CC and) (NP (ADJP (CD 40) (NN mM)) (NN K+)))))) (-RRB- -RRB-) (PP (IN in) (NP (JJ primed) (NNS islets))))) (: ;) (ADVP (RB however)) (, ,) (S (NP (NP (DT the) (NN ability)) (PP (IN of) (NP (JJ high) (NN glucose))) (S (VP (TO to) (VP (VB augment) (NP (NN _PROT2_) (NN activity)))))) (VP (VBD bore) (NP (DT no) (NN relationship)) (PP (TO to) (NP (DT the) (JJ secretory) (NN response))))))) |ET|
-1 |BT| (S1 (S (S (NP (NN MPA)) (ADVP (RB markedly)) (VP (VBD inhibited) (NP (NN _PROT1_)) (PP (IN in) (NP (DT both) (NNS conditions))))) (: ;) (S (ADVP (RB however)) (, ,) (NP (NN _PROT2_) (NN secretion)) (VP (VBD was) (ADVP (RB only)) (VP (VBN inhibited) (PRN (-LRB- -LRB-) (PP (IN by) (NP (CD 46) (NN %))) (-RRB- -RRB-)) (PP (IN in) (NP (JJ primed) (NNS islets)))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT2_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT2_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT1_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT1_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT2_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT1_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS data)) (VP (VBP indicate) (SBAR (SBAR (IN that) (S (NP (NP (DT an) (JJ adequate) (NN level)) (PP (IN of) (NP (NN GTP)))) (VP (VBZ is) (ADJP (JJ critical) (PP (IN for) (NP (NP (NN glucose) (POS 's) (NN potentiation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT_) (NN secretion))) (PP (IN in) (NP (JJ primed) (NNS islets))))))))) (CC but) (SBAR (IN that) (S (NP (NN _PROT_) (NN activation)) (VP (VP (MD can) (ADVP (RB clearly)) (VP (VB be) (VP (VBN dissociated) (PP (IN from) (NP (NN _PROT1_) (NN secretion)))))) (CC and) (ADVP (RB therefore)) (VP (MD cannot) (VP (VB be) (NP (NP (DT the) (JJ major) (NN cause)) (PP (IN of) (NP (NP (NN glucose) (POS 's) (NN augmentation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -induced)) (NN _PROT2_) (NN secretion))))))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (NN Regulation)) (PP (IN of) (NP (NN _PROT1_) (NN secretion))) (PP (IN via) (NP (NP (JJ ATP-sensitive) (NN K+) (NN channel)) (JJ independent) (NNS mechanisms)))) (: :) (NP (NP (NN role)) (PP (IN of) (NP (NN _PROT2_) (NN _PROT2_))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (JJ further) (NN addition)) (PP (IN of) (NP (NP (NP (NN carbachol)) (, ,) (NP (NP (DT an) (NN agonist)) (SBAR (WHNP (WDT that)) (S (VP (VBZ activates) (NP (NP (DT an) (NN isozyme)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_))) (ADJP (JJ distinct) (PP (IN from) (NP (NP (DT that)) (VP (VBN activated) (PP (IN by) (NP (NN glucose)))))))) (, ,) (PP (ADVP (RB together)) (IN with) (NP (NN K+)))))))) (, ,) (NP (ADJP (CD 20) (NN mM)) (NN glucose)) (, ,) (CC plus) (NP (NN diazoxide))))) (VP (VBD resulted) (PP (IN in) (NP (NP (DT a) (JJ sustained) (NN amplification)) (PP (IN of) (NP (NP (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NP (NP (NN mouse)) (CONJP (CC but) (RB not)) (NP (NN rat))) (NNS islets)))))))))) |ET|
+1 |BT| (S1 (S (NP (DT The) (NN inability) (S (VP (TO to) (VP (VB activate) (NP (NP (DT a) (ADJP (ADJP (JJ nutrient-)) (CC and) (ADJP (JJ calcium-regulated))) (NN _PROT1_) (NN _PROT1_) (NN isozyme)) (PP (IN in) (NP (NN mouse) (NNS islets))) (PP (TO to) (NP (NP (DT the) (JJ same) (NN extent)) (PP (IN as) (PP (IN in) (NP (NN rat) (NNS islets))))))))))) (VP (VBZ appears) (S (VP (TO to) (VP (VB account) (, ,) (PP (ADVP (IN at) (JJS least)) (IN in) (NP (NN part))) (, ,) (PP (IN for) (NP (DT these) (JJ different) (NN _PROT2_) (JJ secretory) (NNS responses))) (PP (IN under) (NP (DT these) (JJ unique) (NNS conditions))))))))) |ET|
-1 |BT| (S1 (S (ADVP (RB Further)) (, ,) (NP (NP (DT the) (JJ _PROT1_) (NN activation)) (PP (IN of) (NP (NP (NN IK)) (PRN (-LRB- -LRB-) (NP (NN sl)) (-RRB- -RRB-))))) (VP (VBD was) (ADVP (RB effectively)) (VP (VBN antagonized) (PP (PP (IN by) (NP (NP (QP (QP (CD 5) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -8)) (-RRB- -RRB-))) (NN mol/l) (NN U-73122)) (CC or) (NP (NP (QP (QP (CD 5) (CC x) (CD 10)) (PRN (-LRB- -LRB-) (NP (CD -6)) (-RRB- -RRB-))) (NN mol/l) (NN 2-nitro-4-carboxyphenyl) (NN N)) (, ,) (NP (NP (NN N-diphenylcarbamate)) (PRN (-LRB- -LRB-) (NP (NP (NNS inhibitors)) (PP (IN of) (NP (DT the) (NN cell) (NN membrane) (NN phospholipase) (NN C)))) (-RRB- -RRB-)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN by) (NP (ADJP (RB intracellularly) (VBN applied)) (NN heparin)))))) (PRN (-LRB- -LRB-) (NP (NP (JJ selective) (NN inhibitor)) (PP (IN of) (NP (ADJP (NN _PROT2_) (-LRB- -LRB-) (NN IP3) (-RRB- -RRB-) (JJ -induced)) (NN Ca2+) (NN release) (NNS channels)))) (-RRB- -RRB-)))) |ET|
-1 |BT| (S1 (S (NP (NP (DT The) (NNS data)) (VP (VBN obtained))) (VP (VBP suggest) (S (LST (-LRB- -LRB-) (LS i) (-RRB- -RRB-)) (PP (IN that) (S (NP (JJ selective) (NN _PROT1_) (NNS receptors)) (VP (VBP are) (ADJP (JJ present) (PP (IN on) (NP (NP (DT the) (NNS membranes)) (PP (IN of) (NP (JJ guinea-pig) (JJ antral) (NN smooth) (NN muscle) (NNS cells))))))))) (, ,) (LST (-LRB- -LRB-) (LS ii) (-RRB- -RRB-)) (PP (IN that) (S (S (NP (DT the) (JJ oxytocin-related) (NN relaxation)) (VP (MD may) (VP (VB result) (PP (IN from) (NP (NP (DT the) (NN activation)) (PP (IN of) (NP (ADJP (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (JJ -sensitive)) (NN K+) (NN conductivity))))) (PP (IN via) (NP (NP (NN activation)) (PP (IN of) (NP (NP (JJ _PROT2_) (NN release)) (PP (IN of) (NP (NN Ca2+))) (PP (IN from) (NP (NP (DT the) (JJ submembrane) (JJ located) (NNS cisternae)) (PP (IN of) (NP (NP (DT the) (JJ sarcoplasmic) (NN reticulum)) (NN Ca2+) (NNS stores)))))))))))) (CC and) (S (LST (-LRB- -LRB-) (LS iii) (-RRB- -RRB-)) (PP (IN in) (NP (NN turn))) (, ,) (NP (DT this)) (VP (VBZ evokes) (NP (NP (DT a) (JJ non-inactivating) (NN component)) (PP (IN of) (NP (NN IK)))) (, ,) (S (VP (VBG hyperpolarizing) (NP (DT the) (NN cell) (NN membrane)))))))))))) |ET|
+1 |BT| (S1 (S (NP (DT The) (NNS results)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP (NP (JJ potent) (NNS antioxidants)) (, ,) (PP (JJ such) (IN as) (NP (NNS _PROT1_))) (, ,)) (VP (VP (VB protect) (NP (NP (NN MM-LDL)) (PP (IN from) (NP (NN lipoperoxidation))))) (CC and) (VP (VB preserve) (NP (PRP$ their) (NN ability) (S (VP (TO to) (ADVP (RB efficiently)) (VP (VB deliver) (NP (NN _PROT2_)) (PP (TO to) (NP (NNS cells)))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT2_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT2_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT1_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT2_)) (CC and) (NP (NN _PROT_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT1_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (S (VP (TO To) (VP (VB elucidate) (NP (NP (DT the) (JJ pathophysiologic) (NN significance)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN _PROT_)))) (PP (IN in) (NP (NP (DT the) (NN effect)) (PP (IN of) (NP (NNS TZDs))) (PP (IN on) (NP (NP (NN glucose) (NN metabolism)) (CC and) (NP (NN energy) (NN expenditure)))))))))) (, ,) (S (NP (PRP we)) (VP (VBD examined) (NP (PRP$ their) (JJ basal) (NN mRNA) (NNS levels)) (PP (IN in) (NP (NP (NP (DT the) (ADJP (ADJP (VBD WAT)) (, ,) (ADJP (JJ brown))) (NN adipose) (NN tissue)) (PRN (-LRB- -LRB-) (NP (NN BAT)) (-RRB- -RRB-))) (, ,) (CC and) (NP (NP (JJ skeletal) (NN muscle)) (PP (IN from) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT a) (NN rat) (NN model)) (PP (IN of) (NP (NP (NN NIDDM)) (CC and) (NP (NN obesity)))) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect)))) (, ,) (CC and) (NP (NP (VBN investigated) (NN expression)) (PP (IN of) (NP (NP (DT the) (NNS genes)) (VP (VBG encoding) (NP (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (PP (PP (IN in) (NP (JJ Wistar) (JJ fatty) (NNS rats))) (CC and) (PP (IN in) (NP (JJ Wistar) (JJ lean) (NNS rats)))) (PP (IN with) (NP (NP (JJ 2-week) (JJ oral) (NN administration)) (PP (IN of) (NP (NP (NP (CD 3) (NN mg) (NN x) (CD kg) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-) (NN x) (NN day) (-LRB- -LRB-) (CD -1) (-RRB- -RRB-)) (NN pioglitazone)) (, ,) (NP (DT a) (JJ TZD) (NN derivative)))))))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN _PROT1_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN by) (NP (NNS TZDs))) (PP (IN in) (NP (DT the) (VBD WAT) (NP (CC and) (NP (NN BAT)) (PP (IN in) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT an) (JJ obese) (NN model)) (PP (IN with) (NP (NN _PROT2_) (NN receptor) (NN defect))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN adipose) (NN _PROT_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS TZDs))))) (ADVP (FW in) (FW vitro)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN _PROT1_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN by) (NP (NNS TZDs))) (PP (IN in) (NP (DT the) (VBD WAT) (NP (CC and) (NP (NN BAT)) (PP (IN in) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT an) (JJ obese) (NN model)) (PP (IN with) (NP (NN _PROT_) (NN receptor) (NN defect))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN adipose) (NN _PROT2_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS TZDs))))) (ADVP (FW in) (FW vitro)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS results)) (ADVP (RB clearly)) (VP (VBP demonstrate) (SBAR (SBAR (IN that) (S (NP (NN _PROT_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN upregulated) (PP (IN by) (NP (NNS TZDs))) (PP (IN in) (NP (DT the) (VBD WAT) (NP (CC and) (NP (NN BAT)) (PP (IN in) (NP (NP (JJ Wistar) (JJ fatty) (NNS rats)) (, ,) (NP (NP (DT an) (JJ obese) (NN model)) (PP (IN with) (NP (NN _PROT1_) (NN receptor) (NN defect))))))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP (NN adipose) (NN _PROT2_) (NN gene) (NN expression)) (VP (VBZ is) (VP (VBN increased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (NNS TZDs))))) (ADVP (FW in) (FW vitro)))))))))) |ET|
+1 |BT| (S1 (S (S (NP (NP (VBN Enhanced) (JJ phosphoinositide) (NN hydrolysis)) (PP (IN via) (NP (NP (NN overexpression)) (PP (IN of) (NP (NN _PROT1_) (NN _PROT1_) (NN beta1) (NN or) (NN delta1)))))) (VP (VBZ inhibits) (NP (NP (JJ stimulus-induced) (NN _PROT2_) (NN release)) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells)))))) (. .))) |ET|
-1 |BT| (S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (VBN enhanced) (JJ phosphoinositide) (NN hydrolysis))) (PP (IN on) (NP (NN _PROT1_) (NN secretion))))))) (, ,) (NP (NP (NP (JJ phosphoinositide-specific) (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN PLCbeta1)) (-RRB- -RRB-))) (CC or) (NP (NN _PROT_))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells))) (PP (IN via) (NP (JJ adenoviral) (NNS vectors)))))) (. .))) |ET|
-1 |BT| (S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (VBN enhanced) (JJ phosphoinositide) (NN hydrolysis))) (PP (IN on) (NP (NN _PROT1_) (NN secretion))))))) (, ,) (NP (NP (NP (JJ phosphoinositide-specific) (NN _PROT_) (NN _PROT_)) (PRN (-LRB- -LRB-) (NP (NN PLCbeta1)) (-RRB- -RRB-))) (CC or) (NP (NN _PROT2_))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells))) (PP (IN via) (NP (JJ adenoviral) (NNS vectors)))))) (. .))) |ET|
-1 |BT| (S1 (S (S (S (VP (TO To) (VP (VB study) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (VBN enhanced) (JJ phosphoinositide) (NN hydrolysis))) (PP (IN on) (NP (NN _PROT_) (NN secretion))))))) (, ,) (NP (NP (NP (JJ phosphoinositide-specific) (NN _PROT1_) (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NN PLCbeta1)) (-RRB- -RRB-))) (CC or) (NP (NN _PROT2_))) (VP (VBD was) (VP (VBN overexpressed) (PP (IN in) (NP (NN insulinoma) (NN MIN6) (NNS cells))) (PP (IN via) (NP (JJ adenoviral) (NNS vectors)))))) (. .))) |ET|
+1 |BT| (S1 (S (NP (NP (JJ Constitutive) (NN expression)) (PP (IN of) (NP (NN PKABA1)))) (ADVP (RB drastically)) (VP (VBD suppressed) (NP (NP (NN expression)) (PP (IN of) (NP (NP (ADJP (ADJP (JJ low-)) (CC and) (ADJP (JJ high-pI))) (NP (NP (NN _PROT1_)) (CC and) (NP (NN protease))) (NNS genes)) (VP (VBN induced) (PP (IN by) (NP (NN _PROT2_)))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (JJ Long-term) (NNS changes)) (PP (IN in) (NP (NP (NN gastrin)) (, ,) (NP (NN cholecystokinin)) (CC and) (NP (NN _PROT1_)))) (PP (IN in) (NN response) (TO to) (NP (NN _PROT2_) (NN treatment)))))) |ET|
+1 |BT| (S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ repeated) (NNS injections)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBP influence) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (ADJP (RB vagally) (VBN controlled)) (NNS hormones)) (PP (JJ such) (IN as) (NP (NP (NN gastrin)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT2_)) (CC and) (NP (NN somatostatin)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ endogenous) (NN _PROT_)) (CC and) (NP (NN glucose))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ repeated) (NNS injections)) (PP (IN of) (NP (NN _PROT1_)))) (VP (VBP influence) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (ADJP (RB vagally) (VBN controlled)) (NNS hormones)) (PP (JJ such) (IN as) (NP (NP (NN gastrin)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT_)) (CC and) (NP (NN somatostatin)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ endogenous) (NN _PROT2_)) (CC and) (NP (NN glucose))))))))))))))) |ET|
-1 |BT| (S1 (S (NP (DT The) (JJ present) (NN study)) (VP (VBD was) (VP (VBN designed) (S (VP (TO to) (VP (VB investigate) (SBAR (WHADVP (WRB how)) (S (NP (NP (JJ repeated) (NNS injections)) (PP (IN of) (NP (NN _PROT_)))) (VP (VBP influence) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (ADJP (RB vagally) (VBN controlled)) (NNS hormones)) (PP (JJ such) (IN as) (NP (NP (NN gastrin)) (, ,) (NP (NP (NN cholecystokinin)) (PRN (-LRB- -LRB-) (NP (NN CCK)) (-RRB- -RRB-))) (, ,) (NP (NN _PROT1_)) (CC and) (NP (NN somatostatin)))))) (, ,) (CONJP (RB as) (RB well) (IN as)) (PP (IN of) (NP (NP (JJ endogenous) (NN _PROT2_)) (CC and) (NP (NN glucose))))))))))))))) |ET|
+1 |BT| (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CC both) (NP (NN _PROT1_)) (CC and) (NP (NN CCK))) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN _PROT2_) (NN treatment))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (NP (QP (CD 3) (CC and) (CD 10)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (NN injection)) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (: ;) (NP (NN _PROT_) (NN p) (NN <) (CD 0.01)) (, ,) (NP (NN CCK) (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-))))))))))) |ET|
-1 |BT| (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CC both) (NP (NN _PROT1_)) (CC and) (NP (NN CCK))) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN _PROT_) (NN treatment))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (NP (QP (CD 3) (CC and) (CD 10)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (NN injection)) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (: ;) (NP (NN _PROT2_) (NN p) (NN <) (CD 0.01)) (, ,) (NP (NN CCK) (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-))))))))))) |ET|
-1 |BT| (S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (NP (CC both) (NP (NN _PROT_)) (CC and) (NP (NN CCK))) (NNS levels)) (VP (VBD were) (VP (VBN decreased) (PP (IN in) (NP (NP (NN response)) (PP (TO to) (NP (DT the) (NN _PROT1_) (NN treatment))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN measured) (PP (NP (QP (CD 3) (CC and) (CD 10)) (NNS days)) (IN after) (NP (NP (DT the) (JJ last) (NN injection)) (PRN (-LRB- -LRB-) (NP (NN ANOVA)) (: ;) (NP (NN _PROT2_) (NN p) (NN <) (CD 0.01)) (, ,) (NP (NN CCK) (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-))))))))))) |ET|
-1 |BT| (S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ alpha2-adrenoreceptor) (NN agonist) (NN clonidine)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN microgram/kg) (NN intracerebroventricularly)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 3) (NNS days)) (IN after) (NP (DT the) (JJ 5-day) (NN treatment) (NN period))) (PP (IN with) (NP (NP (NN _PROT1_)) (CC or) (NP (NN saline)))))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT2_)) (CC and) (NP (NN CCK))))) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ _PROT_) (NNS rats)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS controls)) (VP (VBG receiving) (NP (NP (NN clonidine)) (ADVP (RB only))))))))))) |ET|
-1 |BT| (S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ alpha2-adrenoreceptor) (NN agonist) (NN clonidine)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN microgram/kg) (NN intracerebroventricularly)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 3) (NNS days)) (IN after) (NP (DT the) (JJ 5-day) (NN treatment) (NN period))) (PP (IN with) (NP (NP (NN _PROT1_)) (CC or) (NP (NN saline)))))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT_)) (CC and) (NP (NN CCK))))) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ _PROT2_) (NNS rats)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS controls)) (VP (VBG receiving) (NP (NP (NN clonidine)) (ADVP (RB only))))))))))) |ET|
-1 |BT| (S1 (S (SBAR (WHADVP (WRB When)) (S (NP (NP (DT the) (JJ alpha2-adrenoreceptor) (NN agonist) (NN clonidine)) (PRN (-LRB- -LRB-) (NP (CD 2.5) (NN microgram/kg) (NN intracerebroventricularly)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN administered) (PP (NP (CD 3) (NNS days)) (IN after) (NP (DT the) (JJ 5-day) (NN treatment) (NN period))) (PP (IN with) (NP (NP (NN _PROT_)) (CC or) (NP (NN saline)))))))) (, ,) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN _PROT1_)) (CC and) (NP (NN CCK))))) (VP (VBD increased) (ADVP (RB significantly)) (PRN (-LRB- -LRB-) (NP (NN p) (NN <) (CD 0.05)) (-RRB- -RRB-)) (PP (IN in) (NP (DT the) (JJ _PROT2_) (NNS rats)))) (, ,) (SBAR (WHADVP (WRB when)) (S (VP (VBN compared) (PP (TO to) (NP (NP (JJ saline-treated) (NNS controls)) (VP (VBG receiving) (NP (NP (NN clonidine)) (ADVP (RB only))))))))))) |ET|
+1 |BT| (S1 (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (DT these) (NNS results)) (VP (VBP show) (SBAR (IN that) (S (NP (NN _PROT1_)) (VP (VBZ induces) (NP (NP (JJ long-lasting) (NNS changes)) (PP (IN in) (NP (NP (NN plasma) (NNS levels)) (PP (IN of) (NP (NP (NN gastrin)) (, ,) (NP (NN CCK)) (CC and) (NP (NN _PROT2_))))))) (, ,) (PP (IN without) (S (VP (VBG affecting) (NP (NP (NP (NN somatostatin)) (CC or) (NP (NN glucose))) (NNS levels))))))))))) |ET|
-1 |BT| (S1 (S (NP (NP (NN Plasma) (NN _PROT1_)) (, ,) (CC and) (NP (NP (DT some) (ADJP (RB functionally) (JJ related)) (NNS peptides)) (PRN (-LRB- -LRB-) (NP (NP (NN CCK)) (, ,) (NP (NN gastrin)) (, ,) (NP (NN somatostatin)) (CC and) (NP (NN _PROT2_))) (-RRB- -RRB-))) (, ,)) (VP (VBD were) (VP (VBN measured) (PP (IN by) (NP (JJ standard) (NN radioimmunoassay) (NNS techniques))))))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (JJ _PROT1_) (NNS elements)) (VP (VBN conserved) (PP (IN in) (NP (JJ cereal) (NN _PROT2_) (NNS genes))))) (VP (VBP are) (RB not) (VP (VBN included) (PP (IN in) (NP (NP (DT the) (JJ 5'-upstream) (NN region)) (PP (IN of) (NP (NP (NN Rep1)) (CC or) (NP (NN RepA)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (, ,) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN mitogen) (JJ activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NN kinase)) (ADVP (RB alone))))) (VP (VBZ is) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB promote) (NP (NN _PROT1_) (NN secretion))))))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MAP) (NN kinase)))) (VP (MD will) (VP (VB reduce) (NP (NN _PROT2_) (NN secretion)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (NP (NN _PROT_) (NN _PROT_)) (CC or) (NP (NN phosphatidylinositol) (NN 3-kinase))) (VP (VBP are) (ADVP (RB additionally)) (VP (VBN inhibited)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (, ,) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN mitogen) (JJ activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NN kinase)) (ADVP (RB alone))))) (VP (VBZ is) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB promote) (NP (NN _PROT1_) (NN secretion))))))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MAP) (NN kinase)))) (VP (MD will) (VP (VB reduce) (NP (NN _PROT_) (NN secretion)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (NP (NN _PROT2_) (NN _PROT2_)) (CC or) (NP (NN phosphatidylinositol) (NN 3-kinase))) (VP (VBP are) (ADVP (RB additionally)) (VP (VBN inhibited)))))))))) |ET|
-1 |BT| (S1 (S (S (NP (PRP$ Our) (NNS data)) (VP (VBP demonstrate) (, ,) (SBAR (IN that) (S (NP (NP (NN activation)) (PP (IN of) (NP (NP (NN mitogen) (JJ activated) (NN protein) (-LRB- -LRB-) (NN MAP) (-RRB- -RRB-) (NN kinase)) (ADVP (RB alone))))) (VP (VBZ is) (ADJP (JJ sufficient) (S (VP (TO to) (VP (VB promote) (NP (NN _PROT_) (NN secretion))))))))))) (, ,) (IN whereas) (S (NP (NP (NN inhibition)) (PP (IN of) (NP (NN MAP) (NN kinase)))) (VP (MD will) (VP (VB reduce) (NP (NN _PROT1_) (NN secretion)) (SBAR (WHADVP (RB only) (WRB when)) (S (NP (NP (NN _PROT2_) (NN _PROT2_)) (CC or) (NP (NN phosphatidylinositol) (NN 3-kinase))) (VP (VBP are) (ADVP (RB additionally)) (VP (VBN inhibited)))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NN Tolbutamide)) (CC and) (NP (NN diazoxide))) (VP (VBP modulate) (NP (NP (NP (NP (NP (NN _PROT1_) (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN signaling)) (CC and) (NP (NN _PROT2_) (NN secretion))) (PP (IN in) (NP (NNS beta-cells))))))) |ET|
-1 |BT| (S1 (S (NP (PRP We)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide)) (, ,) (SBAR (WHNP (WDT which)) (S (ADJP (ADJP (JJ close)) (CC or) (ADJP (JJ open)) (NP (NP (NP (NP (JJ ATP-sensitive) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NN K) (-LRB- -LRB-) (NN ATP) (-RRB- -RRB-) (NNS channels)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP interact) (PP (PP (IN with) (NP (NP (NP (NP (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS signals)) (PP (IN in) (NP (NN HIT-T15) (CC and) (NN mouse) (NNS beta-cells))))) (CC and) (PP (IN with) (NP (NP (JJ _PROT2_) (NN _PROT_) (NN secretion)) (PP (IN from) (NP (NN HIT-T15) (NNS cells)))))))))))) |ET|
-1 |BT| (S1 (S (NP (PRP We)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide)) (, ,) (SBAR (WHNP (WDT which)) (S (ADJP (ADJP (JJ close)) (CC or) (ADJP (JJ open)) (NP (NP (NP (NP (JJ ATP-sensitive) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NN K) (-LRB- -LRB-) (NN ATP) (-RRB- -RRB-) (NNS channels)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP interact) (PP (PP (IN with) (NP (NP (NP (NP (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS signals)) (PP (IN in) (NP (NN HIT-T15) (CC and) (NN mouse) (NNS beta-cells))))) (CC and) (PP (IN with) (NP (NP (JJ _PROT_) (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NN HIT-T15) (NNS cells)))))))))))) |ET|
+1 |BT| (S1 (S (NP (PRP We)) (VP (VBD examined) (SBAR (IN whether) (S (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide)) (, ,) (SBAR (WHNP (WDT which)) (S (ADJP (ADJP (JJ close)) (CC or) (ADJP (JJ open)) (NP (NP (NP (NP (JJ ATP-sensitive) (NN K)) (-LRB- -LRB-) (CC +) (-RRB- -RRB-)) (NNS channels)) (PRN (-LRB- -LRB-) (NP (NN K) (-LRB- -LRB-) (NN ATP) (-RRB- -RRB-) (NNS channels)) (-RRB- -RRB-))) (, ,) (ADVP (RB respectively))))) (, ,)) (VP (VBP interact) (PP (PP (IN with) (NP (NP (NP (NP (JJ _PROT_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NNS signals)) (PP (IN in) (NP (NN HIT-T15) (CC and) (NN mouse) (NNS beta-cells))))) (CC and) (PP (IN with) (NP (NP (JJ _PROT1_) (NN _PROT2_) (NN secretion)) (PP (IN from) (NP (NN HIT-T15) (NNS cells)))))))))))) |ET|
+1 |BT| (S1 (S (ADVP (RB Thus)) (NP (NP (NN tolbutamide)) (CC and) (NP (NN diazoxide))) (VP (VBP regulate) (NP (NP (CC both) (NP (NP (NP (JJ _PROT1_) (NN Ca)) (PRN (-LRB- -LRB-) (NP (NN 2+)) (-RRB- -RRB-))) (NN signaling)) (CC and) (NP (NN _PROT2_) (NN secretion))) (PP (IN from) (NP (JJ pancreatic) (NNS beta-cells)))) (PP (IN by) (S (VP (VBG modulating) (NP (NP (NP (NN K)) (PRN (-LRB- -LRB-) (NP (NN ATP)) (-RRB- -RRB-))) (NNS channels))))) (, ,) (S (ADVP (RB thereby)) (VP (VBG determining) (NP (JJ voltage-sensitive) (NN Ca) (-LRB- -LRB-) (NN 2+) (-RRB- -RRB-) (NN influx))))))) |ET|
-1 |BT| (S1 (S (NP (PRP We)) (VP (VBD examined) (PP (IN for) (NP (DT the) (JJ first) (NN time))) (PP (IN in) (NP (NP (NP (JJ young) (NNS men) (NNS effects)) (PP (IN of) (NP (NP (JJ intravenous) (NNS injections)) (PP (IN of) (NP (NP (NN _PROT1_)) (PRN (-LRB- -LRB-) (NP (NP (NP (QP (CD 4x50) (CC or) (CD 100)) (NN microg)) (, ,) (S (NP (NN n)) (VP (JJ =) (NP (CD 9) (CC and) (CD 11)) (, ,) (ADVP (RB respectively)) (, ,) (PP (IN at) (NP (NP (CD 22.00)) (, ,) (NP (CD 23.00)) (, ,) (NP (CD 24.00)) (CC and) (NP (CD 01.00))))))) (VP (VBN compared) (PP (TO to) (NP (NN saline))))) (-RRB- -RRB-)))))) (PP (IN on) (NP (NP (DT the) (JJ sleep) (NN electroencephalogram)) (PRN (-LRB- -LRB-) (NP (NN EEG)) (: ;) (S (VP (VBN recorded) (PP (IN from) (NP (CD 23.00) (TO to) (CD 07.00))))) (-RRB- -RRB-))))) (CC and) (NP (NP (JJ nocturnal) (NN secretion)) (PP (IN of) (NP (NP (NP (JJ adrenocorticotrophic) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN ACTH)) (-RRB- -RRB-))) (, ,) (NP (NN cortisol)) (, ,) (NP (NP (NN growth) (NN hormone)) (PRN (-LRB- -LRB-) (NP (NN GH)) (-RRB- -RRB-))) (, ,) (NP (NN prolactin)) (CC and) (NP (NN _PROT2_)))))))))) |ET|
-1 |BT| (S1 (S (NP (DT These) (NNS results)) (VP (VBP suggest) (SBAR (IN that) (S (NP (NN T3)) (VP (MD may) (VP (VB increase) (NP (NP (NN _PROT1_) (NN family) (NN expression)) (ADJP (JJ independent) (PP (IN of) (NP (NN _PROT2_) (NN action)))))))))))) |ET|
+1 |BT| (S1 (S (NP (NP (NP (NN _PROT1_) (NNS effects)) (PP (IN on) (NP (NP (JJ pulsatile) (NN gonadotropin) (VBG releasing) (NN hormone) (NN secretion)) (PP (IN from) (NP (DT the) (JJ adult) (NN rat) (NN hypothalamus)))))) (CC and) (NP (NP (NN interaction)) (PP (IN with) (NP (NP (NP (NN cocaine)) (CC and) (NP (NN amphetamine))) (NP (NP (VBN regulated) (NN transcript) (NN peptide)) (CC and) (NP (NN _PROT2_) (NN _PROT2_))))))) (VP (VBP [In) (NP (NN Process) (NP (NNP Citation)))) (-RRB- -RSB-))) |ET|
+1 |BT| (S1 (S (S (NP (NN _PROT1_)) (VP (MD may) (VP (VB act) (PP (IN as) (NP (NP (DT a) (JJ negative) (NN feedback) (NN signal)) (PP (TO to) (NP (NP (DT the) (JJ hypothalamic) (NN control)) (PP (IN of) (NP (NN appetite))))))) (PP (IN through) (NP (NP (NP (NN suppression)) (PP (IN of) (NP (NP (NP (NN _PROT2_) (NN _PROT2_)) (PRN (-LRB- -LRB-) (NP (NN NPY)) (-RRB- -RRB-))) (NN secretion)))) (CC and) (NP (NP (NN stimulation)) (PP (IN of) (NP (NP (NN cocaine)) (CC and) (NP (NP (NN amphetamine) (JJ regulated) (NN transcript)) (PRN (-LRB- -LRB-) (NP (NN CART)) (-RRB- -RRB-))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (S (NP (PRP We)) (VP (VBD aimed) (PP (IN at) (S (VP (VBG studying) (NP (NP (DT the) (NNS effects)) (PP (IN of) (NP (NP (NN _PROT1_)) (, ,) (NP (NN CART)) (CC and) (NP (NN _PROT2_)))) (PP (IN on) (NP (NP (DT the) (JJ hypothalamic) (NN control)) (PP (IN of) (NP (DT the) (JJ pituitary-gonadal) (NN system))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (S (NP (NP (DT The) (NN increase)) (PP (IN in) (NP (NN GnRH) (NN pulse) (NN amplitude))) (VP (VBN caused) (PP (IN by) (NP (NN _PROT1_))))) (VP (VBD was) (ADVP (RB totally)) (VP (VBN prevented) (PP (IN by) (NP (NP (NN coincubation)) (PP (IN with) (NP (NP (DT an) (JJ anti-CART) (NN antiserum)) (SBAR (IN whereas) (S (NP (PRP it)) (VP (VBD was) (RB not) (VP (VBN affected) (PP (IN by) (NP (NP (NN coincubation)) (PP (IN with) (NP (NP (DT the) (NN _PROT2_) (JJ Y5-receptor) (NN antagonist)) (PRN (-LRB- -LRB-) (NP (CD 10) (-LRB- -LRB-) (CD -7) (-RRB- -RRB-) (NN M)) (-RRB- -RRB-))))))))))))))))) (. .))) |ET|
-1 |BT| (S1 (S (S (PP (IN In) (NP (NN conclusion))) (, ,) (NP (NP (NN _PROT1_)) (CC and) (NP (NN _PROT2_))) (VP (VBP show) (NP (NP (JJ separate) (JJ permissive) (NNS effects)) (PP (IN on) (NP (NP (NN GnRH) (NN secretion)) (PP (IN in) (NP (DT the) (JJ adult) (NN rat) (NN hypothalamus)))))))) (. .))) |ET|
+1 |BT| (S1 (S (NP (NP (DT The) (NN induction)) (PP (IN of) (NP (NN _PROT1_))) (VP (VBN triggered) (PP (IN by) (NP (JJ _PROT2_) (NN _PROT2_))) (PP (IN in) (NP (JJ barley) (NNS embryos))))) (VP (VBZ is) (VP (VBN repressed) (PP (IN by) (NP (NNS sugars))))))) |ET|
-1 |BT| (S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN glucose)) (VP (VBZ represses) (NP (NN _PROT1_) (NN signalling)) (ADVP (RB late)) (PP (IN along) (NP (DT this) (NN hormone) (NN transduction) (NN pathway))) (, ,) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ _PROT2_) (JJ transcriptional) (NN activator)) (PRN (-LRB- -LRB-) (NP (NN GAMYB)) (-RRB- -RRB-))))))) (VP (VBN needed) (PP (IN for) (NP (NN _PROT_) (NN induction)))))))))) |ET|
-1 |BT| (S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN glucose)) (VP (VBZ represses) (NP (NN _PROT1_) (NN signalling)) (ADVP (RB late)) (PP (IN along) (NP (DT this) (NN hormone) (NN transduction) (NN pathway))) (, ,) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ _PROT_) (JJ transcriptional) (NN activator)) (PRN (-LRB- -LRB-) (NP (NN GAMYB)) (-RRB- -RRB-))))))) (VP (VBN needed) (PP (IN for) (NP (NN _PROT2_) (NN induction)))))))))) |ET|
-1 |BT| (S1 (S (NP (PRP$ Our) (NNS results)) (VP (VBP indicate) (SBAR (IN that) (S (NP (NN glucose)) (VP (VBZ represses) (NP (NN _PROT_) (NN signalling)) (ADVP (RB late)) (PP (IN along) (NP (DT this) (NN hormone) (NN transduction) (NN pathway))) (, ,) (ADVP (RB downstream) (PP (IN of) (NP (NP (NN transcription)) (PP (IN of) (NP (NP (DT the) (JJ _PROT1_) (JJ transcriptional) (NN activator)) (PRN (-LRB- -LRB-) (NP (NN GAMYB)) (-RRB- -RRB-))))))) (VP (VBN needed) (PP (IN for) (NP (NN _PROT2_) (NN induction)))))))))) |ET|
